

## Communications to the Editor

[Chem. Pharm. Bull.]  
33(10)4618-4620(1985)

A NEW SOLID-PHASE SYNTHESIS OF RIBOOLIGONUCLEOTIDES USING THE 3'-  
PHOSPHORO-*p*-ANISIDATE PROTECTING GROUP FOR STEPWISE SYNTHESIS IN THE  
3'-DIRECTION

Shigenori Iwai, Miyuki Asaka, Hideo Inoue and Eiko Ohtsuka\*  
Faculty of Pharmaceutical Sciences, Hokkaido University,  
Kita-12, Nishi-6, Kita-ku, Sapporo 060, Japan

A nonaribonucleotide CAGGUAAGU has been synthesized by the phosphotriester solid-phase method. The 5'-linked 2'-*O*-tetrahydrofuran-yl-*N*-benzoylcytidine 3'-*O*-(*o*-chlorophenyl) phosphate was used as the starting material and the chain was elongated in the 3'-direction by removal of the phosphoro-*p*-anisidate group using isoamyl nitrite under neutral conditions.

KEYWORDS — nonaribooligonucleotide; splice site RNA; phosphoro-*p*-anisidate method; isoamyl nitrite

Solid-phase procedures for the synthesis of deoxyribooligonucleotides have been facilitated by improvements in the phosphodiester activation method and the introduction of the phosphoramidite method.<sup>1)</sup> In the ribo-series, the phosphotriester solid-phase synthesis has been investigated only to a limited extent<sup>2)</sup> due to difficulties encountered when using combinations of protecting groups for the 2'- and 5'-hydroxyl groups. We have previously reported a synthesis of ribooligonucleotides on a polystyrene support in the 5'-direction by selective removal of the 5'-dimethoxytrityl group with zinc bromide<sup>3)</sup> in the presence of a 2'-tetrahydrofuran-yl protecting group.<sup>2c)</sup> In this communication we describe a solid-phase synthesis of ribooligonucleotides involving elongation of a chain in the 3'-direction by selective removal of the 3'-phosphoro-*p*-anisidate protecting group with isoamyl nitrite under neutral conditions. In this approach, the dedimethoxytritylation to yield the starting material (**1**) with zinc bromide can be performed in solution and **1** can be purified even if the reaction with zinc bromide does not go to completion. As shown in Chart 1, the 3'-phosphodiester end of the growing chain was activated with 1-(mesitylenesulfonyl)-3-nitro-1,2,4-triazole (MSNT).<sup>4)</sup> The key intermediates *N*-protected-2'-*O*-tetrahydrofuran-yl-nucleoside 3'-*O*-(*p*-chlorophenyl) phosphoro-*p*-anisidates(**1**) were prepared by phosphorylation of *N*-protected 5'-*O*-dimethoxytrityl-2'-*O*-tetrahydrofuran-yl-nucleosides<sup>5)</sup> with *o*-chlorophenyl *N*-*p*-methoxyphenylchlorophosphoramidate<sup>6)</sup> followed by treatment with zinc bromide.<sup>7)</sup> The starting nucleotide (**1b**) was joined to 1% cross-linked aminomethylene polystyrene via the activated succinyl derivative of 2'-*O*-

tetrahydrofuranyl-*N*-benzoylcytidine 3'-(*o*-chlorophenyl) phosphoro-*p*-anisidate (**2b**) using conditions described for the reaction with *N*-benzoyldeoxyadenosine 3'-*O*-(*o*-chlorophenyl) phosphoro-*p*-anisidate.<sup>8)</sup> The unchanged amino groups on the support were blocked by acetylation with acetic anhydride-pyridine(2:3, v/v). The content of the nucleotide was estimated by formation of a picrate<sup>9)</sup> and 0.09 mmol/g of the amino groups was found to have reacted in a yield of 83%.

The nucleotide resin (**3b**)(5  $\mu$ mol) was used for the synthesis of a nonanucleotide CAGGUAAGU. The procedures for removal of the anisidate with isoamyl nitrate to give **4b** and condensation of mononucleotides (20  $\mu$ mol each) to yield, e.g., **5** are summarized in Table I. MSNT was used as the condensing reagent and unreacted phosphodiesteres were blocked by methylation. 2',3'-*O*-Ethoxymethylideneuridine<sup>10)</sup> was used for the last condensation.

Deblocking of the linked nonamer (**6**,  $n=7$ ) was performed by hydrolysis with 1,1,3,3,-tetramethylguanidinium pyridine-2-aldoximate<sup>4)</sup> and by treatment with concentrated ammonia. The tetrahydrofuranyl groups were removed at pH 2.0 using conditions described for the solution-phase synthesis.<sup>7)</sup> The completely deprotected nonanucleotide (**7**) was isolated by gel filtration on Sephadex G-25 and chromatography on DEAE-TOYOPEARL 650S. The product eluted in the last peak was fractionated by high pressure liquid chromatography on C-18 silica gel (Nucleosil 5C<sub>18</sub>) in a yield of ca. 1%, 3.7 A<sub>260</sub> units. The purity and sequence were analyzed by high pressure anion-exchange chromatography on TSK gel DEAE-2SW and by mobility shift analysis.<sup>11)</sup>

Thus the ribononanucleotide containing the 5'-consensus splice junction<sup>12)</sup> was synthesized on a polymer support in the 3'-direction. Analogs of this oligonucleotide can be used for studies of splicing mechanisms in messenger RNAs. The method can be applied to the synthesis of ribooligonucleotide with modifications at the 3'-end by using 3'-substituted nucleosides at the last condensation.




Chart 1

Table I. Procedure for the Synthesis

Step	Solvent or reagent	Amount (ml)	Operation (time)	Number of operations
1	Pyridine	2	wash	2
2	Isoamyl nitrite	0.5		
	Pyridine-acetic acid (1:1, v/v)	2	2.5h <sup>a)</sup>	1
3	Pyridine-acetic acid	2	wash	2
4	0.5 M TAA <sup>b)</sup> in DMF	2	wash	3
5	Dichloromethane	2	wash	3
6	Ether	2	wash	3
7	THF	2	wash	3
8	Pyridine	2	wash	3
9	Pyridine	0.5	coevaporation	3
10	Nucleotide in Pyridine	15 mg in 0.5 ml	coevaporation	1
11	MSNT in pyridine	20 mg in 0.5 ml	30 min <sup>a)</sup>	1
12	Pyridine	2	wash	1
13	10 % MeOH in pyridine	0.5	10 min <sup>a)</sup>	1
	MSNT	20 mg		

a) at 30°C, b) Triethylammonium acetate.

## REFERENCES AND NOTES

- 1) For a review : E. Ohtsuka, M. Ikehara and D. Soll, Nucleic Acids Res., **10**, 6553 (1982).
- 2) a) E. Ohtsuka, H. Takashima and M. Ikehara, Tetrahedron Lett., **22**, 765 (1981);  
b) G. A. van der Marel, G. Wille, and J. H. van Boom, Recl. Trav. Chim. Pays-Bas, **101**, 241 (1982); c) E. Ohtsuka, J. Matsugi, T. Doi and M. Ikehara, Chem. Pharm. Bull., in press.
- 3) R. Kierzek, H. Ito, R. Blatt and K. Itakura, Tetrahedron Lett., **22**, 376 (1981).
- 4) C. B. Reese, R. C. Titmus and L. Yau, Tetrahedron Lett., **1978**, 2727.
- 5) E. Ohtsuka, M. Okubo, A. Yamane and M. Ikehara, Chem. Pharm. Bull., **31**, 1910 (1983).
- 6) E. Ohtsuka, Y. Taniyama, R. Marumoto, H. Sato, H. Hirosaki and M. Ikehara, Nucleic Acids Res., **10**, 2597 (1982).
- 7) E. Ohtsuka, A. Yamane and M. Ikehara, Nucleic Acids Res., **11**, 1325 (1983).
- 8) E. Ohtsuka, Y. Taniyama, S. Iwai, T. Yoshida and M. Ikehara, Chem. Pharm. Bull., **32**, 85 (1984).
- 9) H. Ito, Y. Ike, S. Ikuta and K. Itakura, Nucleic Acids Res., **10**, 1755 (1982).
- 10) J. Smrt and S. Chladek, Collect Czech. Chem. Commun., **31**, 2978 (1966).
- 11) F. Sanger, J. E. Donelson, A. R. Coulson, H. Kössel and D. Fischer, Proc. Natl. Acad. Sci. U.S.A., **70**, 1209 (1973).
- 12) S. M. Mount, Nucleic Acid Res., **10**, 459 (1982).

(Received July 25, 1985)